Skip to content
    Ally Bridge Group logo

    Ally Bridge Group

    New York, New York, United StatesFounded 2013
    ally-bridge.comLinkedIn
    Biotech & Life SciencesHealthcare

    Ally Bridge Group is a global healthcare investment management firm focused on high-impact life science innovation across private and public markets. Founded in 2013 by Frank Yu, the firm manages assets from offices in New York and Hong Kong.

    40% of their portfolio is in Healthcare. Deal activity increased 250% year-over-year (7 deals in the last 12 months). Average disclosed round size is $112.9M (across 86 rounds with reported amounts).

    Find people at Ally Bridge Group on Goldilocks AI

    Portfolio

    71

    Fund Size

    —

    Top Stage

    Bridge

    Last 12 Mo

    7

    Team

    AL

    Andrew Lam, PharmD

    Managing Director, Head of Biotech

    CW

    Charles Wong, CPA

    Managing Director, Chief Operating Officer, Chief Financial Officer

    KR

    Kevin Reilly

    Managing Director, Head of Medtech

    RY

    Reese Yeh

    Managing Director

    ZS

    Zain Shekhani

    Managing Director, Head of Investor Relations

    EY

    Emma Yang

    Director of Legal

    CS

    Carlos Solorzano, PhD

    Principal

    TC

    Tinnie Chau, CFA

    Principal, Investor Relations

    JW

    Jonathan Wang, CFA, CPA

    Vice President

    KL

    Keith Lee

    Vice President

    KC

    Kelly Cheng, CPA

    Vice President

    MM

    Megan MacDonagh

    Vice President

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    101 investments
    CompanyRoundAmountDate
    Solve Therapeutics logoSolve TherapeuticsBridge$120MSep 2026
    Calyxo logoCalyxoSeries F$40MApr 2026
    Ovid Therapeutics Inc. logoOvid Therapeutics Inc.Unknown$60MMar 2026
    Biobeat logoBiobeatSeries B$50MJan 2026
    Solve Therapeutics logoSolve TherapeuticsUnknown$120MJan 2026
    Climb Bio logoClimb BioUnknown$110MJan 2026
    First Tracks logoFirst TracksUnknown$80MJan 2026
    Biobeat logoBiobeatSeries B$50MDec 2025
    Solve Therapeutics logoSolve TherapeuticsSeries D$120MNov 2025
    Galvanize Therapeutics logoGalvanize TherapeuticsSeries C$100MSep 2025
    Galvanize logoGalvanizeBridge—Sep 2025
    Cardiac Dimensions logoCardiac DimensionsSeries E$53MMar 2025
    Arbor Biotechnologies logoArbor BiotechnologiesSeries C$73.9MMar 2025
    VitalConnect logoVitalConnectSeries F$30MJan 2025
    Lexeo logoLexeoUnknown$80MJan 2025
    Cardiac Dimensions logoCardiac DimensionsSeries E$53MJan 2025
    INSIGHTEC logoINSIGHTECGrowth$150MJun 2024
    Transcarent logoTranscarentSeries D$126MMay 2024
    Alumis logoAlumisSeries C$259MMar 2024
    ProfoundBio logoProfoundBioSeries B$112MFeb 2024
    Transcarent logoTranscarentSeries D$126MJan 2024
    Kestra Medical Technologies logoKestra Medical TechnologiesUnknown$196MJan 2024
    INSIGHTEC logoINSIGHTECGrowth$150MJan 2024
    AAeglea BiotherapeuticsBridge—Aug 2023
    Lightforce Orthodontics logoLightforce OrthodonticsSeries D—Aug 2023
    Page 1 of 5

    Top Co-Investors

    T. Rowe Price16 shared
    Sofinnova Partners12 shared
    OrbiMed12 shared
    Venrock12 shared
    Perceptive Advisors11 shared
    Cormorant Asset Management11 shared
    Catalio Capital Management9 shared
    Norwest Venture Partners8 shared
    RA Capital Management8 shared
    Deerfield8 shared
    EDBI7 shared
    Hillhouse Investment7 shared
    Elevage Medical Technologies7 shared
    Surveyor Capital7 shared
    Piper Heartland Healthcare Capital7 shared
    Gilmartin Capital6 shared
    New Enterprise Associates6 shared
    ARCH Venture Partners6 shared
    CDH Investments5 shared
    Hopu Investments5 shared

    Last updated: 7 October 2026